The endogenous cannabinoid, anandamide, inhibits dopamine transporter function by a receptor-independent mechanism

Journal of Neurochemistry

Volumn 112, Issue 6, 2010, Pages 1454-1464

  Oz, Murat ^a,b   Jaligam, Vanaja ^a   Galadari, Sehamuddin ^b   Petroianu, George ^b   Shuba, Yaroslav M ^c   Shippenberg, Toni S ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^c BOGOMOLETZ INSTITUTE OF PHYSIOLOGY   (Ukraine)

Author keywords

Anandamide; Cannabinoids; Dopamine transporter; HEK293 cells

Indexed keywords

4 [4 (DIMETHYLAMINO)STYRYL] N METHYLPYRIDINIUM; ANANDAMIDE; ARACHIDONIC ACID; BENZYLSULFONYL FLUORIDE; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DOPAMINE; DOPAMINE TRANSPORTER; INDOMETACIN; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; METHANANDAMIDE; PERTUSSIS TOXIN; PYRIDINIUM DERIVATIVE; UNCLASSIFIED DRUG; YELLOW FLUORESCENT PROTEIN;

ARTICLE; BIOTINYLATION; CELL SURFACE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOPAMINE RELEASE; HUMAN; HUMAN CELL; IC 50; MOLECULAR IMAGING; PRIORITY JOURNAL;

ALANINE; ARACHIDONIC ACIDS; BENZAMIDES; CALCIUM; CARBAMATES; CELL LINE, TRANSFORMED; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOCANNABINOIDS; ENZYME INHIBITORS; HUMANS; LUMINESCENT PROTEINS; MICROSCOPY, CONFOCAL; PHENYLMETHYLSULFONYL FLUORIDE; POLYUNSATURATED ALKAMIDES; RECEPTORS, CANNABINOID; RECEPTORS, SCAVENGER; SILICONE ELASTOMERS; TIME FACTORS; TRANSFECTION; TRITIUM; TROPANES;

EID: 77349085737     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2009.06557.x     Document Type: Article

References (48)

1. Abadji V., Lin S., Taha G., Griffin G., Stevenson L. A., Pertwee R. G. Makriyannis A. (1994) (R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J. Med. Chem. 37, 1889 1893.
2. Adams I. B., Ryan W., Singer M., Thomas B. F., Compton D. R., Razdan R. K. Martin B. R. (1995) Evaluation of cannabinoid receptor binding and in vivo activities for anandamide analogs. J. Pharmacol. Exp. Ther. 273, 1172 1181.
3. Amara S. G. Kuhar M. J. (1993) Neurotransmitter transporters: recent progress. Annu. Rev. Neurosci. 16, 73 93.
4. Barann M., Molderings G., Brüss M., Bönisch H., Urban B. W. Göthert M. (2002) Direct inhibition by cannabinoids of human 5-HT3A receptors: probable involvement of an allosteric modulatory site. Br. J. Pharmacol. 137, 589 596.
5. Bolan E. A., Kivell B., Jaligam V. et al. (2007) D2 receptors regulate dopamine transporter function via an extracellular signal-regulated kinases 1 and 2-dependent and phosphoinositide 3 kinase-independent mechanism. Mol. Pharmacol. 71, 1222 1232.
6. Brown A. J. (2007) Novel cannabinoid receptors. Br. J. Pharmacol. 152, 567 575.
7. Butt C., Alptekin A., Shippenberg T. Oz M. (2008) Endogenous cannabinoid anandamide inhibits nicotinic acetylcholine receptor function in mouse thalamic synaptosomes. J. Neurochem. 105, 1235 1243.
8. Case G. D., Vanderkooi J. M. Scarpa A. (1974) Physical properties of biological membranes determined by the fluorescence of the calcium ionophore A23187. Arch. Biochem. Biophys. 162, 174 185.
9. Chalon S. (2006) Omega-3 fatty acids and monoamine neurotransmission. Prostaglandins Leukot. Essent. Fatty Acids 75, 259 269.
10. Chemin J., Monteil A., Perez-Reyes E., Nargeot J. Lory P. (2001) Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide. EMBO J. 20, 7033 7040.
11. Chen N., Appell M., Berfield J. L. Reith M. E. A. (2003) Inhibition by arachidonic acid and other fatty acids of dopamine uptake at the human dopamine transporter. Eur. J. Pharmacol. 478, 89 95.
12. Cravatt B. F. Lichtman A. H. (2002) The enzymatic inactivation of the fatty acid amide class of signaling lipids. Chem. Phys. Lipids 121, 135 148.
13. De Petrocellis L., Bisogno T., Davis J. B., Pertwee R. G. Di Marzo V. (2000) Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Lett. 483, 52 56.
14. Fadda P., Scherma M., Spano M. S., Salis P., Melis V., Fattore L., Fratta W. (2006) Cannabinoid self-administration increases dopamine release in the nucleus accumbens. Neuroreport. 17 (15 1629 1632.
15. Fisyunov A., Tsintsadze V., Min R., Burnashev N. Lozovaya N. A. (2006) Cannabinoids modulate the P-type high voltage-activated calcium currents in Purkinje neurons. J. Neurophysiol. 96, 1267 1277.
16. Foster J. D., Cervinski M. A., Gorentla B. K. Vaughan R. A. (2006) Regulation of the dopamine transporter by phosphorylation. Handb. Exp. Pharmacol. 175, 197 214.
17. 2+ regulates amphetamine-induced dopamine efflux and currents mediated by the human dopamine transporter. Mol. Pharmacol. 66, 137 1343.
18. 9- Tetrahydrocannabinol and endogenous cannabinoid anandamide directly potentiate the function of glycine receptors. Mol. Pharmacol. 69, 991 997.
19. Howlett A. C., Barth F., Bonner T. I. et al. (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 54, 161 202.
20. Jerman J. C., Gray J., Brough S. J., Ooi L., Owen D., Davis J. B. Smart D. (2002) Comparison of effects of anandamide at recombinant and endogenous rat vanilloid receptors. Br. J. Anaesth. 89, 882 887.
21. Kathuria S., Gaetani S., Fegley D. et al. (2003) Modulation of anxiety through blockade of anandamide hydrolysis. Nat. Med. 9, 76 81.
22. Kim H. I., Kim T. H., Shin Y. K., Lee C. S., Park M. Song J. H. (2005) Anandamide suppression of Na+ currents in rat dorsal root ganglion neurons. Brain Res. 1062, 39 47. (Pubitemid 41612127)
23. L'hirondel M., Chéramy A., Godeheu G. Glowinski J. (1995) Effects of arachidonic acid on dopamine synthesis, spontaneous release, and uptake in striatal synaptosomes from the rat. J. Neurochem. 64, 1406 1409.
24. Lozovaya N., Yatsenko N., Beketov A., Tsintsadze T. Burnashev N. (2005) Glycine receptors in CNS neurons as a target for nonretrograde action of cannabinoids. J. Neurosci. 25, 7499 7506.
25. Mason J. N., Farmer H., Tomlinson I. D., Schwartz J. W., Savchenko V., DeFelice L. J., Rosenthal S. J. Blakely R. D. (2005) Novel fluorescence-based approaches for the study of biogenic amine transporter localization, activity, and regulation. J. Neurosci. Methods 143, 3 25.
26. Melikian H. E. Buckley K. M. (1999) Membrane trafficking regulates the activity of the human dopamine transporter. J. Neurosci. 19, 7699 7710.
27. 2+ in endothelial cells. Br. J. Pharmacol. 126, 1593 1600. (Pubitemid 29182343)
28. Morón J. A., Zakharova I., Ferrer J. V., Merrill G. A., Hope B., Lafer E. M., Lin L. C., Wang J. B., Galli A. Shippenberg T. S. (2003) Mitogen-activated protein kinase regulates dopamine transporter surface expression and dopamine transport capacity. J. Neurosci. 23, 8480 8488.
29. Nicholson R. A., Liao C., Zheng J., David L. S., Coyne L., Errington A. C., Singh G. Lees G. (2003) Sodium channel inhibition by anandamide and synthetic cannabimimetics in brain. Brain Res. 978, 194 204.
30. Oz M. (2006) Receptor-independent actions of cannabinoids on cells membranes: focus on endocannabinoids. Pharmacol. Therap. 111, 114 144.
31. Oz M., Tchugunova Y. Dunn S. M. J. (2000) Endogenous cannabinoid anandamide directly inhibits voltage-dependent calcium fluxes in rabbit T-tubule membrane preparations. Eur. J. Pharmacol. 404, 13 20.
32. 3 receptor-mediated responses in xenopus oocytes. Synapse 46, 150 156.
33. Oz M., Ravindran R., Zhang L. Morales M. (2003) Endogenous cannabinoid, anandamide inhibits neuronal nicotinic acethylcholine receptor-mediated responses in xenopus oocytes. J. Pharmacol. Exp. Ther. 306, 1003 1010.
34. Oz M., Yang K. H., Dinc M. Shippenberg T. S. (2007) The endogenous cannabinoid anandamide inhibits cromakalim-activated K+ currents in follicle-enclosed Xenopus oocytes. J. Pharmacol. Exp. Ther. 323, 547 554.
35. Poling J. S., Rogawski M. A., Salem N. Vicini S. (1996) Anandamide, an endogenous cannabinoid inhibits Shaker-related voltage-gated K+ channels. Neuropharmacology 35, 983 991.
36. Price D. A., Owens W. A., Gould G. G., Frazer A., Roberts J. L., Daws L. C. Giuffrida A. (2007) CB1-independent inhibition of dopamine transporter activity by cannabinoids in mouse dorsal striatum. J. Neurochem. 101, 389 396.
37. Saunders C., Ferrer J. V., Shi L., Chen J., Merrill G., Lamb M. E., Leeb-Lundberg L. M., Carvelli L., Javitch J. A. Galli A. (2000) Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism. Proc. Natl Acad. Sci. USA 97, 6850 6855.
38. Schwartz J. W., Blakely R. D. DeFelice L. J. (2003) Binding and transport in norepinephrine transporters. Real-time, spatially resolved analysis in single cells using a fluorescent substrate. J. Biol. Chem. 278, 9768 9777.
39. Schwartz J. W., Piston D. DeFelice L. J. (2006) Molecular microfluorometry: converting arbitrary fluorescence units into absolute molecular concentrations to study binding kinetics and stoichiometry in transporters. Handb. Exp. Pharmacol. 175, 23 57.
40. Sidló Z., Reggio P. H. Rice M. E. (2008) Inhibition of striatal dopamine release by CB1 receptor activation requires nonsynaptic communication involving GABA, H(2)O(2), and K(ATP) channels. Neurochem. Int. 52, 80 88.
41. Solinas M., Justinova Z., Goldberg S. R. Tanda G. (2006) Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats. J. Neurochem. 98, 408 419.
42. Spivak C. E., Lupica C. R. Oz M. (2007) The endocannabinoid anandamide inhibits the function of alpha4beta2 nicotinic acetylcholine receptors. Mol. Pharmacol. 72, 1024 1032. (Pubitemid 47481425)
43. Steffens M. Feuerstein T. J. (2004) Receptor-independent depression of DA and 5-HT uptake by cannabinoids in rat neocortex - involvement of Na+/K+-ATPase. Neurochem. Int. 44, 529 538.
44. Tanda G., Pontieri F. E. Di Chiara G. (1997) Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 276, 2048 2050.
45. Wise R. A. (1987) The role of reward pathways in the development of drug dependence. Pharmacol. Ther. 35, 227 263.
46. Yeh J. H., Cheng H. H., Huang C. J. et al. (2006) Effect of anandamide on cytosolic Ca(2+) levels and proliferation in canine renal tubular cells. Basic Clin. Pharmacol. Toxicol. 98, 416 422.
47. Zapata A., Kivell B., Han Y. et al. (2007) Regulation of dopamine transporter function and cell surface expression by D3 dopamine receptors. J. Biol. Chem. 282, 35842 35854.
48. Zhang L. Reith M. E. (1996) Regulation of the functional activity of the human dopamine transporter by the arachidonic acid pathway. Eur. J. Pharmacol. 315, 345 354.